Alcidion Bull Sees Chance of a Full-Year Profit -- Market Talk

Dow Jones

Mar 19, 2025

0251 GMT - Alcidion's new bull reckons that the healthcare software provider is well placed to deliver positive annual earnings, and maybe even a net profit. Bell Potter analyst Thomas Wakim raises his recommendation on the stock to buy from hold, telling clients in a note that a combination of a cost-cutting restructure with the signing of a large-scale patient-record contract has already delivered modestly positive 1H Ebitda. With A$8 million in licensing revenue scheduled to be recognized in 2H, Wakim anticipates a welcome shift in profitability across Alcidion's full-year result. Bell Potter keeps a A$0.11 target price on the stock, which is down 1.25% at A$0.079. (stuart.condie@wsj.com)

(END) Dow Jones Newswires

March 18, 2025 22:51 ET (02:51 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2520996123"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2520996123\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2520996123?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-19 10:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2520996123","market":"us","top_or_hot":-1,"title":"Alcidion Bull Sees Chance of a Full-Year Profit -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0251 GMT - Alcidion's new bull reckons that the healthcare software provider is well placed to deliver positive annual earnings, and maybe even a net profit. Bell Potter analyst Thomas Wakim raises his recommendation on the stock to buy from hold, telling clients in a note that a combination of a cost-cutting restructure with the signing of a large-scale patient-record contract has already delivered modestly positive 1H Ebitda. With A$8 million in licensing revenue scheduled to be recognized in 2H, Wakim anticipates a welcome shift in profitability across Alcidion's full-year result. Bell Potter keeps a A$0.11 target price on the stock, which is down 1.25% at A$0.079. (stuart.condie@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 18, 2025 22:51 ET (02:51 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alcidion Bull Sees Chance of a Full-Year Profit -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlcidion Bull Sees Chance of a Full-Year Profit -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-03-19 10:51</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0251 GMT - Alcidion's new bull reckons that the healthcare software provider is well placed to deliver positive annual earnings, and maybe even a net profit. Bell Potter analyst Thomas Wakim raises his recommendation on the stock to buy from hold, telling clients in a note that a combination of a cost-cutting restructure with the signing of a large-scale patient-record contract has already delivered modestly positive 1H Ebitda. With A$8 million in licensing revenue scheduled to be recognized in 2H, Wakim anticipates a welcome shift in profitability across Alcidion's full-year result. Bell Potter keeps a A$0.11 target price on the stock, which is down 1.25% at A$0.079. (stuart.condie@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 18, 2025 22:51 ET (02:51 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7094","symbol_name":"医疗保健技术","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2520996123","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2520996123","pubTimestamp":1742352660,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0251 GMT - Alcidion's new bull reckons that the healthcare software provider is well placed to deliver positive annual earnings, and maybe even a net profit. Bell Potter analyst Thomas Wakim raises his recommendation on the stock to buy from hold, telling clients in a note that a combination of a cost-cutting restructure with the signing of a large-scale patient-record contract has already delivered modestly positive 1H Ebitda. With A$8 million in licensing revenue scheduled to be recognized in 2H, Wakim anticipates a welcome shift in profitability across Alcidion's full-year result. Bell Potter keeps a A$0.11 target price on the stock, which is down 1.25% at A$0.079. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7094":"医疗保健技术","ALC.AU":"ALCIDION GROUP LTD"},"translate_title":"Alcidion Bull看到全年盈利的机会——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALC.AU":0.9},"content_text":"0251 GMT - Alcidion's new bull reckons that the healthcare software provider is well placed to deliver positive annual earnings, and maybe even a net profit. Bell Potter analyst Thomas Wakim raises his recommendation on the stock to buy from hold, telling clients in a note that a combination of a cost-cutting restructure with the signing of a large-scale patient-record contract has already delivered modestly positive 1H Ebitda. With A$8 million in licensing revenue scheduled to be recognized in 2H, Wakim anticipates a welcome shift in profitability across Alcidion's full-year result. Bell Potter keeps a A$0.11 target price on the stock, which is down 1.25% at A$0.079. (stuart.condie@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 18, 2025 22:51 ET (02:51 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}